Fintel reports that on October 1, 2024, EF Hutton initiated coverage of Artelo Biosciences (NasdaqCM:ARTL) with a Buy recommendation.
Analyst Price Forecast Suggests 1,445.46% Upside
As of September 25, 2024, the average one-year price target for Artelo Biosciences is $17.00/share. The forecasts range from a low of $5.05 to a high of $42.00. The average price target represents an increase of 1,445.46% from its latest reported closing price of $1.10 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Artelo Biosciences is 0MM. The projected annual non-GAAP EPS is -1.72.
What is the Fund Sentiment?
There are 9 funds or institutions reporting positions in Artelo Biosciences. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to ARTL is 0.00%, an increase of 23.51%. Total shares owned by institutions increased in the last three months by 81.62% to 45K shares.
What are Other Shareholders Doing?
Geode Capital Management holds 20K shares representing 0.61% ownership of the company. No change in the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 13K shares representing 0.41% ownership of the company. In its prior filing, the firm reported owning 13K shares , representing a decrease of 0.91%. The firm decreased its portfolio allocation in ARTL by 9.55% over the last quarter.
Tower Research Capital LLC holds 6K shares representing 0.18% ownership of the company. In its prior filing, the firm reported owning 5K shares , representing an increase of 16.40%. The firm decreased its portfolio allocation in ARTL by 24.10% over the last quarter.
FNCMX - Fidelity Nasdaq Composite Index Fund holds 3K shares representing 0.10% ownership of the company. No change in the last quarter.
FCFMX - Fidelity Series Total Market Index Fund holds 3K shares representing 0.09% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
